Sandra Spencer

Sandi earned her Ph.D. from the University of North Carolina at Chapel Hill working in the Glish lab on real-time analysis of compounds in organic aerosol particles. She is currently a postdoctoral researcher in the MacCoss lab at the University of Washington working clinical proteomic assay development and quantitative method improvement. Her current projects include development of a kinase activity assay for prediction and monitoring of targeted therapeutic efficacy in cancer, developing an assay to monitor immune checkpoint proteins in formalin fixed paraffin embedded tissues to type solid tumors, and using data independent acquisition to empirically derive targeted assays and molecular signatures for neurodegenerative disease and cognitive decline.